March 26, 2026
By Patty McCarthy, CEO, Faces & Voices of Recovery
In the landscape of public health, few policy shifts have been as consequential or as long-overdue as the 2024 modernization of the rules governing Opioid Treatment Programs (OTPs). For decades, the federal government maintained a rigid, surveillance-heavy approach to treating opioid use disorder (OUD). However, the updates to 42 CFR Part 8 represented a watershed moment, shifting the paradigm from punitive compliance to evidence-based, humane, and patient-centered care.
Today, that progress faces a chilling prospect: a potential reversal of these reforms. As a person in long-term recovery and an advocate for systems of care that prioritize the humanity of the individual, I am compelled to state clearly what is at stake. Rolling back these regulations would not be a neutral administrative adjustment; it would be a policy failure that actively harms those seeking treatment and undermines the very foundation of long-term recovery in the United States.
The Main Facts: A Shift from Mistrust to Medical Care
For most of the last half-century, the federal oversight of OTPs was rooted in a fundamental mistrust—of patients, of clinicians, and of the nature of addiction itself. The system treated OUD not as a chronic, manageable health condition, but as a moral failing that required constant monitoring.
The 2024 regulations dismantled these archaic structures by focusing on several core pillars:
- Removal of Arbitrary Barriers: The elimination of outdated mandates, such as the requirement for a one-year history of opioid use before admission and the discriminatory "failed withdrawal" prerequisites for youth.
- Expanded Access to Take-Home Medication: Shifting the power of decision-making from rigid federal timelines to the clinical judgment of providers.
- Decoupling Counseling from Medication: Acknowledging that recovery is not a one-size-fits-all model; patients can no longer be denied life-saving medication simply because they opt out of mandatory counseling.
- Shared Decision-Making: Elevating the patient to an active partner in their own treatment plan, including choices regarding dosing and supportive services.
These changes were not radical; they were common sense. They aligned federal policy with decades of clinical research and the lived experiences of millions of Americans who have successfully navigated the path to recovery.
A Chronology of Reform and Regression
To understand the current threat, we must look at the timeline of how we arrived here.
1970s–2023: The Era of Surveillance
For decades, OTPs were governed by rules that required daily, in-person clinic attendance for methadone. This "liquid handcuffs" approach effectively tethered patients to clinics, preventing them from holding full-time jobs, attending school, or caring for their families.
2020–2023: The Pandemic Catalyst
The COVID-19 pandemic forced a temporary loosening of these restrictions. When clinics were forced to offer more take-home doses to maintain social distancing, the "sky did not fall." Instead, clinicians and researchers observed higher retention rates and greater patient stability. This period provided the real-world data necessary to justify permanent change.
2024: The Modernization of 42 CFR Part 8
Following years of advocacy and the success of pandemic-era flexibilities, the federal government finalized updates to 42 CFR Part 8. This was celebrated as a victory for public health and a direct acknowledgment of the opioid crisis as a national emergency.
2025–2026: The Political Backlash
In the wake of political shifts, concerns have emerged that these rules may be targeted for repeal. Opponents of the 2024 rules often cite "diversion concerns" or argue that medication-assisted treatment (MAT) needs stricter oversight, ignoring the mountain of evidence that shows strict oversight actually increases the risk of illicit drug use by forcing patients back to the streets when they miss a dose.
Supporting Data: Why Evidence Favors Reform
The case for keeping the 2024 regulations is supported by extensive data provided by the Substance Abuse and Mental Health Services Administration (SAMHSA) and independent researchers.
Retention and Access
Studies have consistently shown that the more flexible the entry requirements, the higher the treatment retention rates. When barriers like "one-year use" requirements are removed, individuals enter treatment at earlier stages of their disorder, preventing further progression of the disease and reducing the likelihood of fatal overdose.
The Impact of Take-Home Doses
Data from the 2020–2023 flexibilities demonstrate that increased take-home access did not lead to an increase in diversion. Conversely, it led to a significant decrease in patient "drop-out." For individuals in rural areas or those with limited transportation, these take-home doses are often the only way to sustain long-term treatment.
The Cost of Inaction
The cost of reversing these policies is measurable in lives lost. In an era dominated by a highly toxic, unpredictable synthetic drug supply, delays in treatment initiation are often fatal. Every hour a patient spends navigating bureaucracy rather than accessing medication is an hour they remain exposed to the danger of the illicit market.
Official Responses and The Policy Debate
The discourse surrounding the potential reversal of these rules has been polarizing.
Proponents of the 2024 Reforms argue that the regulations are the bare minimum required to address a public health crisis. Organizations such as the American Society of Addiction Medicine (ASAM) and various patient advocacy groups have issued statements emphasizing that the 2024 rules are medically sound and ethically necessary.
The Dissenting View typically stems from a focus on the "diversion" of medication. Critics often argue that methadone is a controlled substance that requires "strict controls" to prevent it from entering the illicit market. However, public health experts counter this by noting that the "diversion" of prescription medication is negligible compared to the massive influx of illicit, non-pharmaceutical fentanyl that currently drives the overdose crisis.
SAMHSA’s own official stance has remained consistent: the 2024 regulations were designed to expand access, improve engagement, and support long-term recovery. There has been no official federal data released to date that suggests these reforms have negatively impacted public safety.
Implications: A Question of Recovery Justice
The potential reversal of these regulations is, at its core, a matter of recovery justice.
The Erosion of Autonomy
If the 2024 rules are rolled back, the power dynamic will once again shift from the patient to the administrator. Patients will lose their agency, being reduced to "cases" to be managed rather than individuals to be treated. This return to a system of punitive compliance will destroy the trust that is essential for recovery.
The Disproportionate Burden
Restrictive OTP policies have historically disproportionately impacted the most vulnerable populations. People of color, individuals living in poverty, and those in rural communities have long borne the brunt of rigid, inconvenient clinic requirements. Returning to these policies would widen existing health disparities, effectively barring the most marginalized Americans from the care they need to survive.
The Impact on Quality of Life
Recovery is not merely the absence of substance use; it is the presence of health, connection, and purpose. When a person is required to structure their entire life around daily clinic visits, they are prevented from participating in the very activities that define recovery: working, parenting, and community engagement. By forcing patients back into this cycle of surveillance, we are actively sabotaging their ability to rebuild their lives.
The Path Forward: Why We Cannot Go Back
We are at a crossroads. We have a choice between a system that treats people with dignity and a system that prioritizes control.
The evidence is clear: the 2024 OTP regulations work. They have made treatment more accessible, improved retention rates, and fostered a more humane environment for healing. Reversing them would be an abandonment of the very people we are tasked with helping. It would ignore the hard-won lessons of the pandemic and dismiss the voices of those in recovery who have spent years fighting for a seat at the table.
Policy should be designed to make recovery easier, not harder. If we truly want to address the overdose crisis, we must resist the urge to return to the failed strategies of the past. We owe it to the families who have lost loved ones, to the communities currently struggling, and to the individuals striving for a better future to protect and strengthen these reforms.
The message is clear: Access saves lives, and dignity sustains recovery. To dismantle these protections now would be a tragedy of our own making. We must move forward, not backward.
References:
